Cartesian Therapeutics Soars 4.93% Post-Q1 2025 Results!
StockSavvyWednesday, Jun 4, 2025 7:38 pm ET
1min readCartesian Therapeutics, Inc. rose 4.93% in after-hours trading, following the release of its first-quarter results for the period ending March 31, 2025. The company reported a revenue of $1.1 million, down from $5.84 million in the previous year, and a net loss of $17.71 million, compared to $56.82 million in the prior year. The decrease in net loss and the company's ongoing operations may have contributed to the positive market sentiment.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet